title: Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma.
abstract: Our aim was to establish whether the pretreatment levels of angiogenesis activators and inhibitors can be used to predict clinical responses to treatment that included high-dose chemotherapy with peripheral stem cell support.<br />We analyzed samples and treatment outcomes of 96 patients with MM enrolled in the CMG 2002 randomized clinical trial and treated with induction chemotherapy and high-dose chemotherapy with stem cell support. Concentrations of vascular endothelial growth factor (VEGF), hepatocytar growth factor (HGF), basic fibroblastic growth factor (bFGF), thrombospondin-1 (TSP-1), endostatin, and angiostatin were measured in the peripheral blood plasma and in the bone marrow plasma at diagnosis. <br />Pretreatment HGF concentrations in the peripheral blood plasma as well as in the bone marrow plasma of patients who achieved complete or very good partial response were significantly lower than those in patients who had partial or worse response. Patients with complete or very good partial response had higher TSP-1 levels in the bone marrow plasma than the partial or insufficient response subgroups. There were no correlations between the pretreatment levels of VEGF, bFGF, endostatin, or angiostatin and the treatment response. <br />Pretreatment concentrations of HGF and TSP-1 were predictive factors for treatment response. Patients with low angiogenesis rate as determined by the relative HGF and TSP-1 concentrations were more likely to achieve complete or very good partial response after high-dose chemotherapy.
  
  
  BACKGROUND
  Angiogenesis, cytokines, high-dose chemotherapy, multiple myeloma, therapeutic response.
authors.affiliation: Department of Internal Medicine-Hematooncology, University Hospital Brno, Masaryk University Brno Czech Republic. lpour@fnbrno.cz
authors.forename: L
authors.initials: L
authors.lastname: Pour
authors.forename: H
authors.initials: H
authors.lastname: Svachova
authors.forename: Z
authors.initials: Z
authors.lastname: Adam
authors.forename: Z
authors.initials: Z
authors.lastname: Mikulkova
authors.forename: L
authors.initials: L
authors.lastname: Buresova
authors.forename: L
authors.initials: L
authors.lastname: Kovarova
authors.forename: T
authors.initials: T
authors.lastname: Buchler
authors.forename: M
authors.initials: M
authors.lastname: Penka
authors.forename: J
authors.initials: J
authors.lastname: Vorlicek
authors.forename: R
authors.initials: R
authors.lastname: Hajek
mesh_terms: D000328:Adult; D000368:Aged; D043168:Angiostatins / Q000097:blood; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood; D017228:Hepatocyte Growth Factor / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy*; D018919:Neovascularization, Physiologic; D012189:Retrospective Studies; D019700:Thrombospondin 1 / Q000097:blood*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D019700:Thrombospondin 1; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; D017228:Hepatocyte Growth Factor; D043168:Angiostatins